European Group for Research In Schizophrenia: Phase 3 study withdrawn (Schizophrenia, Psychosis)
European Group for Research In Schizophrenia: Phase 3 study withdrawn (Schizophrenia, Psychosis). Dated 6 days ago, it is inside the fresh trigger window. Score 65/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
Free preview: all 14 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | European Group for Research In Schizophrenia |
| Sponsor type | Academic and hospital |
| Study | A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia |
| NCT ID | NCT07084831 |
| Phase | Phase 3 |
| Status | withdrawn |
| Conditions | Schizophrenia; Psychosis; Cognitive Impairment |
| Intervention types | drug |
| Site countries | Austria, Belgium, Czechia, Denmark, Germany, Hungary, Israel, Italy, Netherlands, Spain |
| Posted | 2025-07-25 |
| Planned start | 2027-01-01 |
| Event | Withdrawn before enrolling |
| Event date | 2026-10-30 |
| Last update posted | 2026-10-30 |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch European Group for Research In Schizophrenia
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock European Group for Research In Schizophrenia + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-30
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: European Group for Research In Schizophrenia and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Timing: High: dated in the last 7 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
65 / 100 Score
- Posted in the last two weeks.
- Stopped early: budget and sites freed up.
- Phase 3: multi-site, larger budget.
What is the ClinicalTrialStartPulse record for European Group for Research In Schizophrenia?
European Group for Research In Schizophrenia's Phase 3 study (NCT07084831) in Schizophrenia, first posted 2025-07-25: withdrawn before enrolling (2026-10-30), in an update posted 2026-10-30.
How does European Group for Research In Schizophrenia compare to other ClinicalTrialStartPulse records?
It is fresh: dated 6 days ago, inside the window where early outreach matters most.
European Group for Research In Schizophrenia vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| European Group for Research In Schizophrenia | NONUS | 2026-10-30 | ||
| Genmab | US | 600 | 91st | 2026-11-03 |
| GlaxoSmithKline | NONUS | 610 | 91st | 2026-11-03 |
| Merck Sharp & Dohme LLC | US | 1,104 | 95th | 2026-11-03 |
Related records
ClinicalTrialStartPulse: Phase 3 ClinicalTrialStartPulse: Outside the US only
How to monitor European Group for Research In Schizophrenia and peer phase 3 records
Get new ClinicalTrialStartPulse records like European Group for Research In Schizophrenia by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.